Ardelyx Inc

ARDXNASDAQ · USD
3.07USD0.00 (0.00%)
442

Ardelyx Inc (ARDX) Covered Calls

Ardelyx Inc trades in the Biotechnology industry with an IV Rank of 97.22%, high versus the past year. ARDX's highest covered call setup is the $7.00 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 126.54% out of the money with 434 days to expiration, a 133.01% return until expiration, and a 111.86% theoretical annualized return. Across the setups shown, annualized returns run from 20.13% to 111.86% at strikes between $3.50 and $7.00, with 154 to 798 days to expiration, as of Nov 13, 2026.

Read more

Running ARDX covered calls helps you generate income from Ardelyx Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ARDX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ARDX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ARDX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ARDX covered call is worth writing.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.

2028-01-214347.00126.540.200.40411.00133.01111.86-6.47+0.287000.20
2027-04-161544.0029.450.150.70106.0034.3081.31-4.85+0.441,6240.55
2028-01-214345.5077.990.104.90251.0081.2368.32-3.24+0.9014.80
2028-01-214345.0061.810.401.50231.0074.7662.87-12.94+0.572,5871.10
2027-04-161543.5013.270.101.3551.0016.5039.12-3.24+0.58781.25
2028-01-214344.0029.450.450.75136.0044.0137.02-14.56+0.511,0700.30
2029-01-197985.0061.810.105.00201.0065.0529.75-3.24+0.9104.90
2029-01-197984.0029.450.455.00136.0044.0120.13-14.56+0.94954.55

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank97.22% High
  • Market cap (M$)772
  • 52 weeks high-63.45%
  • 52 weeks low9.64%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$12.50
    307.17% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-03
  • P/E—
  • Future P/E16.19
  • EPS (ttm)-0.23
  • EPS growth next 5 years—

As of Nov 16, 2026